Technicien Support Production

Conga announces winners of inaugural Inspire and Partner Awards EMEA. October 15, 2026 Conga Connection - AMSTERDAM - October 15, 2026 - Conga, the company lining up commerce, today announced the winners of its inaugural Inspire and Partner Awards EMEA, honoring four customers and three partners for outstanding achievement in commercial transformation. The awards were presented at Conga Connection 2026, held 14-15 October at the Anantara Grand Hotel Krasnapolsky in Amsterdam, where European revenue, commercial and operations leaders gathered under this year's theme, Accelerate What Matters. "Every company says it wants to transform commercial operations, but these four did it, and set a great example for others to follow," said Lisa Martin, Chief Revenue Officer at Conga. "What they have in common isn't just a technology decision. It's the discipline to redesign how their teams price, quote, and contract and consistently turn that work into measurable business impact. Congratulations to all the winners and continued success." Congratulations to the 2026 Inspire Awards EMEA Winners Join the European business briefing. New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day. Innovation Award - Boston Scientific Boston Scientific's EMEA division won the Innovation award for demonstrating a clear and ambitious plan for modern commerce and contracting. Boston Scientific deployed Conga CPQ alongside Conga Rebate Management and saw a 20% year-over-year reduction in quoting time, with 300+ users onboarded and more than 60 quotes within the first five days. Commerce Excellence Award - Cargolux Global all-cargo airline, Cargolux, won the Commerce Excellence award for consistent cross-functional alignment that powered ongoing momentum. Cargolux deployed Conga Price Optimization and Management and CPQ in 180 days across Europe, Asia, and the U.S., replacing manual email quoting with AI-driven pricing logic and automated ancillary charge capture. The program has delivered a 75% reduction in quote time, from 20 minutes to five minutes per rep. Digital Impact Award - Evotec Evotec, a global life science company, won the Digital Impact award for accelerating digital capabilities and outcomes. Working with partner Sopra Steria, Evotec implemented Conga Contracts for Salesforce to generate customer-ready agreements pre-populated with deal-specific terms, enabling teams to create high-quality first drafts in minutes. Template adoption increased to more than 60% of negotiations initiated from an Evotec template, a 50%+ relative improvement, accelerating contracting cycles and allowing the legal team to spend less time on administrative tasks and focus more on strategic risk management and business partnering. Judges' Choice - RHI Magnesita RHI Magnesita, a global leader in refractory products, won the Judges' Choice award for its significant impact. RHI Magnesita is rolling out Conga CPQ across its six regions in a program led by Géraldine Michault, Head of Commercial Excellence & CPQ,, bringing pricing guidance and quoting ownership directly to the sales managers in the field. The judges applaud RHI Magnesita for designing the program hand in hand with the teams who are set to use it every day. Recognizing the Partners Driving Customer Success Conga also recognized three partners whose collaboration, customer focus and commitment to growth are helping organizations turn commercial transformation into meaningful business results across Europe. Presented for the first time, the Partner Awards celebrate the strength of Conga's European partner ecosystem, and the role partners play in helping customers realize lasting value. "This is the first year we have presented Partner Awards in Europe, and it's long overdue," said Martin. "Our European partner ecosystem continues to grow in strength and impact, and these three partners exemplify the collaboration, customer commitment and results that make it so important to our success." Customer Success Advocate Award - Pink Samurais Pink Samurais was recognized for consistently going above and beyond for customers, delivering strong outcomes and bringing a customer-first approach to every engagement. Momentum Builder Award - ArticulateIT ArticulateIT received the Momentum Builder Award for demonstrating exceptional growth, energy and engagement while driving success across the Conga ecosystem. Collaboration Champion Award - Accenture Accenture was named Collaboration Champion for its commitment to joint success and its ability to build strong relationships across Conga teams and the wider partner ecosystem. Commerce Champions: Recognition That Continues Year-Round Recognition at Conga Connection is just one way Conga celebrates the people driving commercial transformation. Through Conga's new Commerce Champions program, customers can share their expertise, showcase their success, and build stronger connections with peers, industry leaders and Conga. Members can participate in opportunities ranging from speaking engagements and customer stories to networking, product feedback and industry visibility, choosing the activities that best align with their interests and goals and getting rewarded in the process. For more information about the Inspire Awards EMEA and Commerce Champions, visit conga.com/inspire-awards-emea and conga.com/customer-advocacy.

Evotec has appointed Dr. Joanna Holbrook as chief scientific officer and a member of its management board, effective November 1, 2026. The Hamburg-based drug discovery company announced the move on October 15. Holbrook has more than 25 years of experience as a scientist and research and development leader. She most recently headed a therapy area at Novo Nordisk. She was previously chief scientific officer at Biomodal and a vice president at BenevolentAI, and began her career at GSK. At Evotec, she will help customers and partners develop new medicines faster and with a higher chance of success. Chief executive officer Dr. Christian Wojczewski said she understands how data and AI are transforming drug discovery.

Evotec announces Chief Scientific Officer transition. Sep 29, 2026, 2:04 AM ET * Dr. Cord Dohrmann to step down as of September 30, 2026 * Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ - Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company. Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said: "I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years. Throughout his tenure, he has played a significant role in strengthening the scientific excellence and innovation culture that Evotec is known for. With his strategic vision for emerging technologies and future scientific trends, Cord has helped establish key capabilities across our platforms, including our iPSC-based technologies and omics capabilities, which have further reinforced Evotec's scientific leadership. Looking to the future, the robust science infrastructure that Cord has built will be an essential component of Evotec's future growth and profitability." Dr. Cord Dohrmann, Evotec's outgoing Chief Scientific Officer, added: "The process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and I have been privileged to contribute to that progress during my time at Evotec. I am grateful for the support and collaboration of the many colleagues I have worked with in that time and look forward to seeing Evotec's scientific expertise continue to create value for customers, partners and patients." Dr. Dohrmann has served as Chief Scientific Officer and Member of the Management Board since 2010. The search for his replacement is ongoing. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investor Relations and Media Contact Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations [email protected] SOURCE Evotec SE NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.